Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

Sponsor
Yeungnam University College of Medicine
Study ID
NCT02597855
Status
Unknown

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
45 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    Total 4 times of intravitreal aflibercept injection was performed
  • Indocyanine green angiography (intraveonus indocyanine green dye) — DRUG
    At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.

Study Details

To compare the short-term effect of intravitreal aflibercept injection between two subtypes of polypoidal choroidal vasculopathy

Key Dates

Start date
Sep 30, 2015
Status verified
Jul 2016
Primary completion
Dec 31, 2015
Completion
Aug 31, 2016

Study Design

Enrollment
29 participants (actual)

Arms

  • Arm: Type 1 polypoidal choroidal vasculopathy
    Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
  • Arm: Type 2 polypoidal choroidal vasculopathy
    Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.

Primary Outcome Measure

Regression Rate of Polyp on Indocyanine Green Angiography [ Time Frame: 3 months ]

Related Studies